A Phase 3 interventional study of rLP2086 and rLP2086 in Meningococcal Vaccine, sponsored by Pfizer. Completed at 99 sites in 8 countries. Open to participants aged 10 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2016-06-14.
Sponsored by Pfizer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is looking at a new vaccine that might prevent meningococcal disease, and will study whether healthy adolescent subjects receiving different lots of vaccine respond in a similar way. The study will also look at the safety of the new vaccine as well as how it is tolerated.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: rLP2086
Biological: rLP2086
Biological: rLP2086
Havrix (HAV) and Saline
Biological: Havrix (HAV) · Biological: Saline
Drug pages: MenB-FHbp vaccine · 4CMenB vaccine
0.5 mL dose, given at 0, 2 and 6 months (lot 1)
Drug pages: MenB-FHbp vaccine · 4CMenB vaccine
0.5 mL dose, given at 0, 2 and 6 months (lot 2)
Drug pages: MenB-FHbp vaccine · 4CMenB vaccine
0.5 mL dose, given at 0, 2 and 6 months (lot 3)
0.5 mL dose or 1.0 mL dose dependent on age given at month 0 and 6.
0.5 mL dose of sterile normal saline for injection.
Percentage of Participants With >=4 Fold Rise in Serum Bactericidal Assay Using Human Complement (hSBA) for 4 Primary Strains and Composite Response (hSBA >=Lower Limit of Quantification [LLOQ] for All 4 Primary Strains Combined) for Group 1
Groups 2 and 3 were included for the Lot consistency analysis for primary strains only (hSBA geometric mean titer). The immunogenicity of two MnB strains in lots 1,2,3 were required to test for lot consistency. These data are presented separately in the other endpoints. The data for all the strains in Lot 1 (Group 1) is sufficient to describe the immunogenicity expected with the vaccine. The analytical plan was included in the protocol and agreement was reach with EMA and FDA. Here, N signifies participants with valid and determinate hSBA titers for given strain at specified time point.
Time frame: One month after third bivalent rLP2086 vaccination
hSBA Geometric Mean Titers (GMTs) for Each of the 2 Primary Test Strains Measured 1 Month After the Third Vaccination With Bivalent rLP2086 Vaccine
Time frame: One month after third bivalent rLP2086 vaccination
Percentage of Participants Reporting Local Reactions (LRs) Within 7 Days After First Vaccination
Time frame: Within 7 Days after first vaccination
Percentage of Participants Reporting Local Reactions (LRs) Within 7 Days After Second Vaccination
Time frame: Within 7 Days after second vaccination
Percentage of Participants Reporting Local Reactions (LRs) Within 7 Days After Third Vaccination
Time frame: Within 7 Days after third vaccination
Percentage of Participants Reporting Systemic Events (SEs) and Antipyretic Use Within 7 Days After First Vaccination
Here, N signifies participants with known values reporting specific characteristic.
Time frame: Within 7 Days after first vaccination
Percentage of Participants Reporting Systemic Events (SEs) and Antipyretic Use Within 7 Days After Second Vaccination
Here, N signifies participants with known values reporting specific characteristic.
Time frame: Within 7 Days after second vaccination
Percentage of Participants Reporting Systemic Events (SEs) and Antipyretic Use Within 7 Days After Third Vaccination
Here, N signifies participants with known values reporting specific characteristic.
Time frame: Within 7 Days after third vaccination
Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After First Vaccination
Time frame: Within 30 days after first vaccination
Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Second Vaccination
Time frame: Within 30 days after second vaccination
Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Third Vaccination
Time frame: Within 30 days after third vaccination
Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Any Vaccination
Time frame: Within 30 days after any vaccination
Percentage of Participants With at Least 1 Serious Adverse Event (SAE) During the Vaccination Phase
Time frame: From the first vaccination up to 1 month after the third vaccination
Percentage of Participants With at Least 1 Serious Adverse Event (SAE) During the Follow-Up Phase
Time frame: From 1 month after third vaccination up to 6 months after the third vaccination
Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Throughout the Study Period
Time frame: From the first vaccination up to 6 month after the third vaccination
Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After First Vaccination
Time frame: Within 30 days after first vaccination
Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Second Vaccination
Time frame: Within 30 days after second vaccination
Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Third Vaccination
Time frame: Within 30 days after third vaccination
Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Any Vaccination
Time frame: Within 30 days after any vaccination
Percentage of Participants With at Least 1 Medically Attended AE During the Vaccination Phase
Time frame: From the first vaccination up to 1 month after the third vaccination
Percentage of Participants With at Least 1 Medically Attended AE During the Follow-Up Phase
Time frame: From 1 month after third vaccination up to 6 months after the third vaccination
Percentage of Participants With at Least 1 Medically Attended AE Throughout the Study Period
Time frame: From the first vaccination up to 6 month after the third vaccination
Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After First Vaccination
Time frame: Within 30 days after first vaccination
Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Second Vaccination
Time frame: 30 days after second vaccination
Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Third Vaccination
Time frame: Within 30 days after third vaccination
Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Any Vaccination
Time frame: Within 30 Days After any Vaccination
Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition During the Vaccination Phase
Time frame: From the first vaccination up to 1 month after the third vaccination
Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition During the Follow-Up Phase
Time frame: From 1 month after third vaccination up to 6 months after the third vaccination
Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Throughout the Study Period
Time frame: From the first vaccination up to 6 month after the third vaccination
Percentage of Participants With at Least 1 Adverse Event (AE) WIthin 30 Days After First Vaccination
Time frame: Within 30 days after first vaccination
Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Second Vaccination
Time frame: Within 30 days after second vaccination
Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Third Vaccination
Time frame: Within 30 days after third vaccination
Percentage of Participants With at Least 1 Adverse Event Within 30 Days After Any Vaccination
Time frame: Within 30 Days after any vaccination
Percentage of Participants With at Least 1 Adverse Event During the Vaccination Phase
Time frame: From the first vaccination up to 1 month after the third vaccination
Percentage of Participants Reporting at Least 1 Immediate AE After First Vaccination
Time frame: Within 30 minutes after first vaccination
Percentage of Participants Reporting at Least 1 Immediate AE After Second Vaccination
Time frame: Within 30 minutes after second vaccination
Percentage of Participants Reporting at Least 1 Immediate AE After Third Vaccination
Time frame: Within 30 minutes after third vaccination
Number of Days Participant's Missed School or Work Due to AE During the Vaccination Phase
Time frame: From the first vaccination up to 1 month after the third vaccination
Percentage of Participants With hSBA Titers >=LLOQ for 10 Secondary Strains Before First Vaccination and 1 Month After Third Bivalent rLP2086 Vaccination for Group 1
Groups 2 and 3 were included for the Lot consistency analysis for primary strains only (hSBA geometric mean titer). The immunogenicity of two MnB strains in lots 1, 2, 3 were required to test for lot consistency. These data are presented separately in the other endpoints. The data for all the strains in Lot 1 (Group 1) is sufficient to describe the immunogenicity expected with the vaccine. The analytical plan was included in the protocol and agreement was reach with EMA and FDA.
Time frame: Before first vaccination, 1 month after third vaccination
Percentage of Participants With hSBA Titers >=1:4, >=1:8, >=1:16, >=1:32, >=1:64, >=1:128 for Each of the 10 Secondary Strains, Before Vaccination 1 and 1 Month After the Third Bivalent rLP2086 Vaccination for Group 1
Groups 2 and 3 were included for the Lot consistency analysis for primary strains only (hSBA geometric mean titer). The immunogenicity of two MnB strains in lots 1, 2, 3 were required to test for lot consistency. These data are presented separately in the other endpoints. The data for all the strains in Lot 1 (Group 1) is sufficient to describe the immunogenicity expected with the vaccine. The analytical plan was included in the protocol and agreement was reach with EMA and FDA.
Time frame: Before first vaccination, 1 month after third vaccination (Vac)
hSBA Geometric Mean Titers (GMTs) for Each of the 10 Secondary Strains Before First Vaccination and 1 Month After the Third Bivalent rLP2086 Vaccination for Group 1
Groups 2 and 3 were included for the Lot consistency analysis for primary strains only (hSBA geometric mean titer). The immunogenicity of two MnB strains in lots 1, 2, 3 were required to test for lot consistency. These data are presented separately in the other endpoints. The data for all the strains in Lot 1 (Group 1) is sufficient to describe the immunogenicity expected with the vaccine. The analytical plan was included in the protocol and agreement was reach with EMA and FDA.
Time frame: Before first vaccination, 1 month after third vaccination
Percentage of Participants Achieving Composite hSBA Titer >=Lower Limit of Quantitation for All 4 Primary Strains Before First Vaccination and 1 Month After Second Bivalent rLP2086 Vaccination for Group 1
Groups 2 and 3 were included for the Lot consistency analysis for primary strains only (hSBA geometric mean titer). The immunogenicity of two MnB strains in lots 1, 2 ,3 were required to test for lot consistency. These data are presented separately in the other endpoints. The data for all the strains in Lot 1 (Group 1) is sufficient to describe the immunogenicity expected with the vaccine. The analytical plan was included in the protocol and agreement was reach with EMA and FDA.
Time frame: Before vaccination 1, 1 Month after Vaccination 2
Percentage of Participants Achieving at Least a 4-Fold Increase in hSBA Titer for Each of the 4 Primary Strains Before First Vaccination to 1 Month After the Second Bivalent rLP2086 Vaccination for Group 1
Groups 2 and 3 were included for the Lot consistency analysis for primary strains only (hSBA geometric mean titer). The immunogenicity of two MnB strains in lots 1, 2, 3 were required to test for lot consistency. These data are presented separately in the other endpoints. The data for all the strains in Lot 1 (Group 1) is sufficient to describe the immunogenicity expected with the vaccine. The analytical plan was included in the protocol and agreement was reach with EMA and FDA.
Time frame: One month after second Bivalent rLP2086 vaccination
Percentage of Participants Achieving at Least a 4-Fold Increase in hSBA Titer for 2 Primary Strains Before First Vaccination to 1 Month After the Second and Third Bivalent rLP2086 Vaccination
Time frame: One month after second, third vaccination
hSBA Geometric Mean Titers (GMTs) for 4 Primary Test Strains and for 2 Primary Test Strains and Before First Vaccination and 1 Month After the Second Bivalent rLP2086 Vaccination
Time frame: Before vaccination (Vac) 1, 1 Month after Vac 2
Percentage of Participants With hSBA Titers >=LLOQ for 4 Primary Test Strains Before First Vaccination, 1 Month After Second and Third Bivalent rLP2086 Vaccination
Time frame: Before Vaccination (Vac) 1, 1 Month after Vac 2, 3
Percentage of Participants With hSBA Titers >=1:4,>=1:8,>=1:16,>=1:32,>=1:64,>=1:128 for Primary Test Strains Before First Vaccination, 1 Month After Second and Third Bivalent rLP2086 Vaccination
Results for PMB80\[A22\] 1:16, PMB2001\[A56\] 1:8, PMB2948\[B24\] 1:8 and PMB2707\[B44\] 1:8 are reported under secondary outcome measure 'Percentage of Participants With hSBA Titers \>=LLOQ for 4 Primary Test Strains Before First Vaccination, 1 Month After Second and Third Bivalent rLP2086 Vaccination.
Time frame: Before Vaccination (Vac) 1, 1 Month after Vac 2, 3
Percentage of Participants Achieving at Least a 3-Fold Increase in hSBA Titer for 4 Primary Test Strains and for Primary Test Starins Before First Vaccination to 1 Month After Third Bivalent rLP2086 Vaccination
Time frame: One month after third bivalent rLP2086 vaccination
Percentage of Participants Achieving at Least a 2-Fold Increase in hSBA Titer for 4 Primary Test Strains and for 2 Primary Test Starins Before First Vaccination to 1 Month After the Third Bivalent rLP2086 Vaccination
Time frame: One month after third bivalent rLP2086 vaccination (Vac)
| Milestone | Group 1 rLP2086 Lot 1 | Group 2 rLP2086 Lot 2 | Group 3 rLP2086 Lot 3 | Group 4 HAV/Saline |
|---|---|---|---|---|
| Started | 1508 | 598 | 587 | 897 |
| Completed | 1353 | 537 | 521 | 815 |
| Not completed | 155 | 61 | 66 | 82 |
| Withdrew: Other | 7 | 1 | 4 | 4 |
| Withdrew: Medication error without associated ae | 1 | 0 | 0 | 1 |
| Withdrew: Pregnancy | 3 | 1 | 2 | 1 |
| Withdrew: No longer meets eligibility criteria | 11 | 2 | 3 | 5 |
| Withdrew: Adverse event | 11 | 5 | 6 | 3 |
| Withdrew: Protocol deviation | 10 | 5 | 6 | 6 |
| Withdrew: Withdrawal by subject | 33 | 14 | 10 | 12 |
| Withdrew: No longer willing to participate | 32 | 13 | 12 | 17 |
| Withdrew: Lost to follow-up | 47 | 20 | 23 | 33 |
Groups 2 and 3 were included for the Lot consistency analysis for primary strains only (hSBA geometric mean titer). The immunogenicity of two MnB strains in lots 1,2,3 were required to test for lot consistency. These data are presented separately in the other endpoints. The data for all the strains in Lot 1 (Group 1) is sufficient to describe the immunogenicity expected with the vaccine. The analytical plan was included in the protocol and agreement was reach with EMA and FDA. Here, N signifies participants with valid and determinate hSBA titers for given strain at specified time point.
| percentage of participants | Group 1 rLP2086 Lot 1 |
|---|---|
| Composite hSBA response (N= 1170) | 83.5 (81.3 to 85.6) |
| PMB80[A22] (N= 1225) | 83.2 (81.0 to 85.2) |
| PMB2001[A56] (N= 1128) | 90.2 (88.4 to 91.9) |
| PMB2948[B24] (N= 1235) | 79.8 (77.4 to 82.0) |
| PMB2707[B44] (N= 1203) | 85.9 (83.8 to 87.8) |
| titer | Group 1 rLP2086 Lot 1 | Group 2 rLP2086 Lot 2 | Group 3 rLP2086 Lot 3 |
|---|---|---|---|
| PMB80[A22] (N= 1266, 518, 492) | 86.8 (82.29 to 91.50) | 84.3 (77.54 to 91.68) | 85.1 (78.26 to 92.47) |
| PMB2948[B24] (N= 1250, 516, 479) | 24.1 (22.70 to 25.48) | 25.3 (23.08 to 27.72) | 25.2 (23.03 to 27.58) |
| percentage of participants | rLP2086 (Lots 1-3) | Group 4 HAV/Saline |
|---|---|---|
| Pain at injection site: Any | 86.7 (85.4 to 88.0) | 47.0 (43.6 to 50.3) |
| Pain at injection site: Mild | 41.1 (39.2 to 43.0) | 36.5 (33.3 to 39.8) |
| Pain at injection site: Moderate | 40.7 (38.8 to 42.5) | 9.9 (8.0 to 12.0) |
| Pain at injection site: Severe | 5.0 (4.2 to 5.9) | 0.6 (0.2 to 1.3) |
| Redness: Any | 16.2 (14.8 to 17.7) | 1.3 (0.7 to 2.3) |
| Redness: Mild | 5.6 (4.7 to 6.5) | 1.2 (0.6 to 2.2) |
| Redness: Moderate | 8.8 (7.7 to 9.9) | 0.1 (0.0 to 0.6) |
| Redness: Severe | 1.9 (1.4 to 2.5) | 0.0 (0.0 to 0.4) |
| Swelling: Any | 18.0 (16.5 to 19.5) | 2.2 (1.4 to 3.4) |
| Swelling: Mild | 8.5 (7.4 to 9.6) | 1.8 (1.0 to 2.9) |
| Swelling: Moderate | 8.8 (7.7 to 9.9) | 0.4 (0.1 to 1.1) |
| Swelling: Severe | 0.7 (0.5 to 1.1) | 0.0 (0.0 to 0.4) |
| percentage of participants | rLP2086 (Lots 1-3) | Group 4 HAV/Saline |
|---|---|---|
| Pain at injection site: Any | 77.7 (76.0 to 79.3) | 15.2 (12.8 to 17.8) |
| Pain at injection site: Mild | 39.4 (37.5 to 41.3) | 12.3 (10.2 to 14.7) |
| Pain at injection site: Moderate | 33.2 (31.4 to 35.1) | 2.7 (1.7 to 4.1) |
| Pain at injection site: Severe | 5.1 (4.2 to 6.0) | 0.1 (0.0 to 0.7) |
| Redness: Any | 12.5 (11.2 to 13.8) | 0.6 (0.2 to 1.4) |
| Redness: Mild | 5.2 (4.4 to 6.2) | 0.6 (0.2 to 1.4) |
| Redness: Moderate | 6.1 (5.2 to 7.1) | 0.0 (0.0 to 0.4) |
| Redness: Severe | 1.1 (0.8 to 1.6) | 0.0 (0.0 to 0.4) |
| Swelling: Any | 13.9 (12.5 to 15.3) | 0.6 (0.2 to 1.4) |
| Swelling: Mild | 6.3 (5.4 to 7.3) | 0.5 (0.1 to 1.2) |
| Swelling: Moderate | 7.3 (6.4 to 8.4) | 0.1 (0.0 to 0.7) |
| Swelling: Severe | 0.2 (0.1 to 0.5) | 0.0 (0.0 to 0.4) |
| percentage of participants | rLP2086 (Lots 1-3) | Group 4 HAV/Saline |
|---|---|---|
| Pain at injection site: Any | 76.0 (74.2 to 77.7) | 34.0 (30.7 to 37.3) |
| Pain at injection site: Mild | 34.1 (32.2 to 36.0) | 23.8 (20.9 to 26.8) |
| Pain at injection site: Moderate | 36.5 (34.6 to 38.5) | 9.9 (7.9 to 12.1) |
| Pain at injection site: Severe | 5.4 (4.5 to 6.4) | 0.4 (0.1 to 1.1) |
| Redness: Any | 13.9 (12.5 to 15.3) | 1.1 (0.5 to 2.1) |
| Redness: Mild | 4.9 (4.1 to 5.8) | 1.0 (0.4 to 1.9) |
| Redness: Moderate | 6.8 (5.8 to 7.9) | 0.1 (0.0 to 0.7) |
| Redness: Severe | 2.2 (1.6 to 2.9) | 0.0 (0.0 to 0.4) |
| Swelling: Any | 15.4 (14.0 to 16.9) | 0.9 (0.3 to 1.7) |
| Swelling: Mild | 7.9 (6.8 to 9.0) | 0.7 (0.3 to 1.6) |
| Swelling: Moderate | 6.8 (5.8 to 7.9) | 0.1 (0.0 to 0.7) |
| Swelling: Severe | 0.7 (0.4 to 1.1) | 0.0 (0.0 to 0.4) |
Here, N signifies participants with known values reporting specific characteristic.
| percentage of participants | rLP2086 (Lots 1-3) | Group 4 HAV/Saline |
|---|---|---|
| Fever >=38 degrees C(N=2679, 890) | 6.4 (5.5 to 7.4) | 1.9 (1.1 to 3.0) |
| Fever 38 to <38.5 degreesC(N=2679, 890) | 4.0 (3.3 to 4.8) | 1.3 (0.7 to 2.3) |
| Fever 38.5 to<39 degrees C(N=2679, 890) | 1.9 (1.5 to 2.5) | 0.3 (0.1 to 1.0) |
| Fever 39 to 40 degrees C(N=2679, 890) | 0.5 (0.3 to 0.8) | 0.2 (0.0 to 0.8) |
| Fever >40 degrees C(N=2679, 890) | 0.0 (0.0 to 0.1) | 0.0 (0.0 to 0.4) |
| Vomiting:Any(N=2681,890) | 3.7 (3.0 to 4.5) | 1.9 (1.1 to 3.0) |
| Vomiting:Mild(N=2681,890) | 2.8 (2.2 to 3.5) | 1.7 (0.9 to 2.8) |
| Vomiting:Moderate(N=2681,890) | 0.9 (0.6 to 1.4) | 0.2 (0.0 to 0.8) |
| Vomiting:Severe(N=2681,890) | 0.0 (0.0 to 0.1) | 0.0 (0.0 to 0.4) |
| Diarrhea:Any(N=2681,890) | 10.6 (9.5 to 11.9) | 12.1 (10.1 to 14.5) |
| Diarrhea:Mild(N=2681,890) | 9.1 (8.0 to 10.3) | 10.9 (8.9 to 13.1) |
| Diarrhea:Moderate(N=2681,890) | 1.3 (0.9 to 1.8) | 1.1 (0.5 to 2.1) |
| Diarrhea:Severe(N=2681,890) | 0.3 (0.1 to 0.5) | 0.1 (0.0 to 0.6) |
| Headache:Any(N=2681,890) | 51.8 (49.9 to 53.8) | 37.2 (34.0 to 40.5) |
| Headache:Mild(N=2681,890) | 28.7 (27.0 to 30.5) | 24.0 (21.3 to 27.0) |
| Headache:Moderate(N=2681,890) | 21.0 (19.4 to 22.6) | 12.5 (10.4 to 14.8) |
| Headache:Severe(N=2681,890) | 2.2 (1.6 to 2.8) | 0.7 (0.2 to 1.5) |
| Fatigue:Any(N=2681,890) | 54.0 (52.1 to 55.9) | 40.3 (37.1 to 43.6) |
| Fatigue:Mild(N=2681,890) | 27.8 (26.1 to 29.5) | 23.5 (20.7 to 26.4) |
| Fatigue:Moderate(N=2681,890) | 23.2 (21.6 to 24.8) | 15.2 (12.9 to 17.7) |
| Fatigue:Severe(N=2681,890) | 3.0 (2.4 to 3.7) | 1.7 (0.9 to 2.8) |
| Chills:Any(N=2681,890) | 25.3 (23.7 to 27.0) | 17.2 (14.8 to 19.8) |
| Chills:Mild(N=2681,890) | 16.2 (14.8 to 17.6) | 13.3 (11.1 to 15.7) |
| Chills:Moderate(N=2681,890) | 8.0 (7.0 to 9.1) | 3.5 (2.4 to 4.9) |
| Chills:Severe(N=2681,890) | 1.2 (0.8 to 1.7) | 0.4 (0.1 to 1.1) |
| Muscle pain:Any(N=2681,890) | 24.4 (22.8 to 26.1) | 19.2 (16.7 to 22.0) |
| Muscle pain:Mild(N=2681,890) | 13.2 (11.9 to 14.5) | 13.5 (11.3 to 15.9) |
| Muscle pain:Moderate(N=2681,890) | 10.1 (9.0 to 11.3) | 5.4 (4.0 to 7.1) |
| Muscle pain:Severe(N=2681,890) | 1.2 (0.8 to 1.6) | 0.3 (0.1 to 1.0) |
| Joint pain:Any(N=2681,890) | 21.9 (20.4 to 23.5) | 13.6 (11.4 to 16.0) |
| Joint pain:Mild(N=2681,890) | 11.8 (10.6 to 13.1) | 8.3 (6.6 to 10.3) |
| Joint pain:Moderate(N=2681,890) | 8.7 (7.7 to 9.8) | 4.6 (3.3 to 6.2) |
| Joint pain:Severe(N=2681,890) | 1.4 (1.0 to 1.9) | 0.7 (0.2 to 1.5) |
| Antipyretic medication(N=2681,890) | 20.7 (19.2 to 22.3) | 10.4 (8.5 to 12.6) |
Here, N signifies participants with known values reporting specific characteristic.
| percentage of participants | rLP2086 (Lots 1-3) | Group 4 HAV/Saline |
|---|---|---|
| Fever >=38 degrees C(N=2540, 840) | 2.0 (1.5 to 2.6) | 1.5 (0.8 to 2.6) |
| Fever 38 to <38.5 degreesC(N=2540, 840) | 1.2 (0.8 to 1.7) | 0.7 (0.3 to 1.5) |
| Fever 38.5 to<39 degrees C(N=2540, 840) | 0.7 (0.4 to 1.1) | 0.7 (0.3 to 1.5) |
| Fever 39 to 40 degrees C(N=2540, 840) | 0.1 (0.0 to 0.3) | 0.1 (0.0 to 0.7) |
| Fever >40 degrees C(N=2540, 840) | 0.0 (0.0 to 0.1) | 0.0 (0.0 to 0.4) |
| Vomiting:Any(N=2545, 843) | 2.2 (1.6 to 2.8) | 1.4 (0.7 to 2.5) |
| Vomiting:Mild(N=2545, 843) | 1.7 (1.3 to 2.3) | 1.1 (0.5 to 2.0) |
| Vomiting:Moderate(N=2545, 843) | 0.4 (0.2 to 0.8) | 0.4 (0.1 to 1.0) |
| Vomiting:Severe(N=2545, 843) | 0.0 (0.0 to 0.1) | 0.0 (0.0 to 0.4) |
| Diarrhea:Any(N=2545, 843) | 7.6 (6.6 to 8.7) | 9.1 (7.3 to 11.3) |
| Diarrhea:Mild(N=2545, 843) | 6.2 (5.3 to 7.2) | 7.6 (5.9 to 9.6) |
| Diarrhea:Moderate(N=2545, 843) | 1.3 (0.9 to 1.8) | 1.2 (0.6 to 2.2) |
| Diarrhea:Severe(N=2545, 843) | 0.1 (0.0 to 0.3) | 0.4 (0.1 to 1.0) |
| Headache:Any(N=2545, 843) | 37.8 (35.9 to 39.8) | 28.1 (25.1 to 31.3) |
| Headache:Mild(N=2545, 843) | 20.2 (18.7 to 21.8) | 15.7 (13.3 to 18.3) |
| Headache:Moderate(N=2545, 843) | 16.0 (14.6 to 17.5) | 10.9 (8.9 to 13.2) |
| Headache:Severe(N=2545, 843) | 1.7 (1.2 to 2.2) | 1.5 (0.8 to 2.6) |
| Fatigue:Any(N=2545, 843) | 38.3 (36.4 to 40.2) | 26.3 (23.4 to 29.4) |
| Fatigue:Mild(N=2545, 843) | 20.6 (19.0 to 22.2) | 13.2 (11.0 to 15.6) |
| Fatigue:Moderate(N=2545, 843) | 15.8 (14.4 to 17.3) | 11.7 (9.6 to 14.1) |
| Fatigue:Severe(N=2545, 843) | 1.9 (1.4 to 2.5) | 1.4 (0.7 to 2.5) |
| Chills:Any(N=2545, 843) | 16.0 (14.6 to 17.4) | 10.3 (8.3 to 12.6) |
| Chills:Mild(N=2545, 843) | 10.6 (9.4 to 11.9) | 8.1 (6.3 to 10.1) |
| Chills:Moderate(N=2545, 843) | 4.8 (4.0 to 5.7) | 1.8 (1.0 to 2.9) |
| Chills:Severe(N=2545, 843) | 0.6 (0.3 to 1.0) | 0.5 (0.1 to 1.2) |
| Muscle pain:Any(N=2545, 843) | 17.8 (16.3 to 19.3) | 10.3 (8.3 to 12.6) |
| Muscle pain:Mild(N=2545, 843) | 8.7 (7.6 to 9.8) | 5.2 (3.8 to 6.9) |
| Muscle pain:Moderate(N=2545, 843) | 7.9 (6.8 to 9.0) | 4.5 (3.2 to 6.1) |
| Muscle pain:Severe(N=2545, 843) | 1.2 (0.8 to 1.7) | 0.6 (0.2 to 1.4) |
| Joint pain:Any(N=2545, 843) | 16.7 (15.3 to 18.2) | 9.1 (7.3 to 11.3) |
| Joint pain:Mild(N=2545, 843) | 8.4 (7.4 to 9.6) | 5.0 (3.6 to 6.7) |
| Joint pain:Moderate(N=2545, 843) | 7.5 (6.5 to 8.6) | 3.4 (2.3 to 4.9) |
| Joint pain:Severe(N=2545, 843) | 0.8 (0.5 to 1.2) | 0.7 (0.3 to 1.5) |
| Antipyretic medication(N=2545, 843) | 13.6 (12.3 to 15.0) | 8.9 (7.1 to 11.0) |
Here, N signifies participants with known values reporting specific characteristic.
| percentage of participants | rLP2086 (Lots 1-3) | Group 4 HAV/Saline |
|---|---|---|
| Fever >=38 degrees C(N=2414, 819) | 2.7 (2.1 to 3.4) | 2.3 (1.4 to 3.6) |
| Fever 38 to <38.5degreesC(N=2414, 819) | 1.8 (1.3 to 2.4) | 1.3 (0.7 to 2.4) |
| Fever 38.5 to<39 degrees C(N=2414, 819) | 0.6 (0.3 to 1.0) | 0.4 (0.1 to 1.1) |
| Fever 39 to 40 degrees C(N=2414, 819) | 0.3 (0.1 to 0.6) | 0.5 (0.1 to 1.2) |
| Fever >40 degrees C(N=2414, 819) | 0.0 (0.0 to 0.2) | 0.1 (0.0 to 0.7) |
| Vomiting:Any(N=2421, 821) | 1.7 (1.3 to 2.3) | 2.2 (1.3 to 3.4) |
| Vomiting:Mild(N=2421, 821) | 1.4 (1.0 to 2.0) | 1.7 (0.9 to 2.8) |
| Vomiting:Moderate(N=2421, 821) | 0.3 (0.1 to 0.6) | 0.5 (0.1 to 1.2) |
| Vomiting:Severe(N=2421, 821) | 0.0 (0.0 to 0.2) | 0.0 (0.0 to 0.4) |
| Diarrhea:Any(N=2421, 821) | 7.7 (6.7 to 8.9) | 7.6 (5.8 to 9.6) |
| Diarrhea:Mild(N=2421, 821) | 6.4 (5.5 to 7.5) | 6.2 (4.7 to 8.1) |
| Diarrhea:Moderate(N=2421, 821) | 1.0 (0.6 to 1.5) | 1.1 (0.5 to 2.1) |
| Diarrhea:Severe(N=2421, 821) | 0.3 (0.1 to 0.6) | 0.2 (0.0 to 0.9) |
| Headache:Any(N=2421, 821) | 35.4 (33.5 to 37.4) | 24.8 (21.9 to 28.0) |
| Headache:Mild(N=2421, 821) | 18.9 (17.3 to 20.5) | 13.5 (11.3 to 16.1) |
| Headache:Moderate(N=2421, 821) | 15.2 (13.8 to 16.7) | 10.4 (8.4 to 12.6) |
| Headache:Severe(N=2421, 821) | 1.3 (0.9 to 1.9) | 1.0 (0.4 to 1.9) |
| Fatigue:Any(N=2421, 821) | 35.9 (34.0 to 37.9) | 24.4 (21.5 to 27.4) |
| Fatigue:Mild(N=2421, 821) | 18.4 (16.9 to 20.0) | 13.5 (11.3 to 16.1) |
| Fatigue:Moderate(N=2421, 821) | 15.2 (13.8 to 16.7) | 10.0 (8.0 to 12.2) |
| Fatigue:Severe(N=2421, 821) | 2.3 (1.8 to 3.0) | 0.9 (0.3 to 1.7) |
| Chills:Any(N=2421, 821) | 13.1 (11.7 to 14.5) | 8.3 (6.5 to 10.4) |
| Chills:Mild(N=2421, 821) | 8.7 (7.6 to 9.9) | 6.5 (4.9 to 8.4) |
| Chills:Moderate(N=2421, 821) | 3.8 (3.1 to 4.7) | 1.7 (0.9 to 2.8) |
| Chills:Severe(N=2421, 821) | 0.5 (0.3 to 0.9) | 0.1 (0.0 to 0.7) |
| Muscle pain:Any(N=2421, 821) | 17.6 (16.1 to 19.1) | 11.1 (9.0 to 13.4) |
| Muscle pain:Mild(N=2421, 821) | 9.5 (8.4 to 10.8) | 6.6 (5.0 to 8.5) |
| Muscle pain:Moderate(N=2421, 821) | 7.2 (6.2 to 8.3) | 4.3 (3.0 to 5.9) |
| Muscle pain:Severe(N=2421, 821) | 0.8 (0.5 to 1.3) | 0.2 (0.0 to 0.9) |
| Joint pain:Any(N=2421, 821) | 16.0 (14.6 to 17.5) | 8.9 (7.0 to 11.1) |
| Joint pain:Mild(N=2421, 821) | 8.9 (7.8 to 10.1) | 5.5 (4.0 to 7.3) |
| Joint pain:Moderate(N=2421, 821) | 5.9 (5.0 to 6.9) | 3.0 (2.0 to 4.5) |
| Joint pain:Severe(N=2421, 821) | 1.2 (0.8 to 1.8) | 0.4 (0.1 to 1.1) |
| Antipyretic medication(N=2421, 821) | 12.7 (11.4 to 14.1) | 6.8 (5.2 to 8.8) |
| percentage of participants | rLP2086 (Lots 1-3) | Group 4 HAV/Saline |
|---|---|---|
| Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After First Vaccination | 0.26 (0.1 to 0.5) | 0.33 (0.1 to 1.0) |
| percentage of participants | rLP2086 (Lots 1-3) | Group 4 HAV/Saline |
|---|---|---|
| Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Second Vaccination | 0.23 (0.1 to 0.5) | 0.23 (0.0 to 0.8) |
| percentage of participants | rLP2086 (Lots 1-3) | Group 4 HAV/Saline |
|---|---|---|
| Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Third Vaccination | 0.32 (0.1 to 0.6) | 0.36 (0.1 to 1.0) |
| percentage of participants | rLP2086 (Lots 1-3) | Group 4 HAV/Saline |
|---|---|---|
| Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Any Vaccination | 0.78 (0.5 to 1.2) | 0.89 (0.4 to 1.7) |
| percentage of participants | rLP2086 (Lots 1-3) | Group 4 HAV/Saline |
|---|---|---|
| Percentage of Participants With at Least 1 Serious Adverse Event (SAE) During the Vaccination Phase | 1.49 (1.1 to 2.0) | 1.90 (1.1 to 3.0) |
| percentage of participants | rLP2086 (Lots 1-3) | Group 4 HAV/Saline |
|---|---|---|
| Percentage of Participants With at Least 1 Serious Adverse Event (SAE) During the Follow-Up Phase | 0.44 (0.2 to 0.8) | 0.60 (0.2 to 1.4) |
| percentage of participants | rLP2086 (Lots 1-3) | Group 4 HAV/Saline |
|---|---|---|
| Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Throughout the Study Period | 1.89 (1.4 to 2.5) | 2.45 (1.5 to 3.7) |
| percentage of participants | rLP2086 (Lots 1-3) | Group 4 HAV/Saline |
|---|---|---|
| Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After First Vaccination | 5.27 (4.5 to 6.2) | 6.69 (5.1 to 8.5) |
| percentage of participants | rLP2086 (Lots 1-3) | Group 4 HAV/Saline |
|---|---|---|
| Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Second Vaccination | 5.91 (5.0 to 6.9) | 6.51 (5.0 to 8.4) |
| percentage of participants | rLP2086 (Lots 1-3) | Group 4 HAV/Saline |
|---|---|---|
| Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Third Vaccination | 5.81 (4.9 to 6.8) | 7.43 (5.7 to 9.4) |
| percentage of participants | rLP2086 (Lots 1-3) | Group 4 HAV/Saline |
|---|---|---|
| Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Any Vaccination | 14.18 (12.9 to 15.6) | 16.61 (14.2 to 19.2) |
| percentage of participants | rLP2086 (Lots 1-3) | Group 4 HAV/Saline |
|---|---|---|
| Percentage of Participants With at Least 1 Medically Attended AE During the Vaccination Phase | 25.29 (23.7 to 27.0) | 27.87 (25.0 to 30.9) |
| percentage of participants | rLP2086 (Lots 1-3) | Group 4 HAV/Saline |
|---|---|---|
| Percentage of Participants With at Least 1 Medically Attended AE During the Follow-Up Phase | 15.61 (14.2 to 17.1) | 16.92 (14.4 to 19.6) |
| percentage of participants | rLP2086 (Lots 1-3) | Group 4 HAV/Saline |
|---|---|---|
| Percentage of Participants With at Least 1 Medically Attended AE Throughout the Study Period | 32.38 (30.6 to 34.2) | 35.56 (32.4 to 38.8) |
| percentage of participants | rLP2086 (Lots 1-3) | Group 4 HAV/Saline |
|---|---|---|
| Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After First Vaccination | 0.00 (0.0 to 0.1) | 0.11 (0.0 to 0.6) |
| percentage of participants | rLP2086 (Lots 1-3) | Group 4 HAV/Saline |
|---|---|---|
| Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Second Vaccination | 0.08 (0.0 to 0.3) | 0.12 (0.0 to 0.6) |
| percentage of participants | rLP2086 (Lots 1-3) | Group 4 HAV/Saline |
|---|---|---|
| Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Third Vaccination | 0.12 (0.0 to 0.4) | 0.00 (0.0 to 0.4) |
| percentage of participants | rLP2086 (Lots 1-3) | Group 4 HAV/Saline |
|---|---|---|
| Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Within 30 Days After Any Vaccination | 0.19 (0.1 to 0.4) | 0.22 (0.0 to 0.8) |
| percentage of participants | rLP2086 (Lots 1-3) | Group 4 HAV/Saline |
|---|---|---|
| Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition During the Vaccination Phase | 0.37 (0.2 to 0.7) | 0.56 (0.2 to 1.3) |
| percentage of participants | rLP2086 (Lots 1-3) | Group 4 HAV/Saline |
|---|---|---|
| Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition During the Follow-Up Phase | 0.20 (0.1 to 0.5) | 0.60 (0.2 to 1.4) |
| percentage of participants | rLP2086 (Lots 1-3) | Group 4 HAV/Saline |
|---|---|---|
| Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition Throughout the Study Period | 0.56 (0.3 to 0.9) | 1.11 (0.5 to 2.0) |
| percentage of participants | rLP2086 (Lots 1-3) | Group 4 HAV/Saline |
|---|---|---|
| Percentage of Participants With at Least 1 Adverse Event (AE) WIthin 30 Days After First Vaccination | 9.51 (8.4 to 10.7) | 10.70 (8.8 to 12.9) |
| percentage of participants | rLP2086 (Lots 1-3) | Group 4 HAV/Saline |
|---|---|---|
| Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Second Vaccination | 11.48 (10.3 to 12.8) | 12.67 (10.5 to 15.1) |
| percentage of participants | rLP2086 (Lots 1-3) | Group 4 HAV/Saline |
|---|---|---|
| Percentage of Participants With at Least 1 Adverse Event (AE) Within 30 Days After Third Vaccination | 9.91 (8.8 to 11.2) | 10.78 (8.8 to 13.1) |
| percentage of participants | rLP2086 (Lots 1-3) | Group 4 HAV/Saline |
|---|---|---|
| Percentage of Participants With at Least 1 Adverse Event Within 30 Days After Any Vaccination | 25.32 (23.7 to 27.0) | 26.76 (23.9 to 29.8) |
| percentage of participants | rLP2086 (Lots 1-3) | Group 4 HAV/Saline |
|---|---|---|
| Percentage of Participants With at Least 1 Adverse Event During the Vaccination Phase | 40.74 (38.9 to 42.6) | 43.70 (40.4 to 47.0) |
| percentage of participants | rLP2086 (Lots 1-3) | Group 4 HAV/Saline |
|---|---|---|
| Percentage of Participants Reporting at Least 1 Immediate AE After First Vaccination | 0.1 (0.0 to 0.4) | 0.2 (0.0 to 0.8) |
| percentage of participants | rLP2086 (Lots 1-3) | Group 4 HAV/Saline |
|---|---|---|
| Percentage of Participants Reporting at Least 1 Immediate AE After Second Vaccination | 0.2 (0.0 to 0.4) | 0.1 (0.0 to 0.6) |
| percentage of participants | rLP2086 (Lots 1-3) | Group 4 HAV/Saline |
|---|---|---|
| Percentage of Participants Reporting at Least 1 Immediate AE After Third Vaccination | 0.1 (0.0 to 0.3) | 0.0 (0.0 to 0.4) |
| days | rLP2086 (Lots 1-3) | Group 4 HAV/Saline |
|---|---|---|
| Number of Days Participant's Missed School or Work Due to AE During the Vaccination Phase | 3.9 ± 6.56 | 4.0 ± 5.19 |
Groups 2 and 3 were included for the Lot consistency analysis for primary strains only (hSBA geometric mean titer). The immunogenicity of two MnB strains in lots 1, 2, 3 were required to test for lot consistency. These data are presented separately in the other endpoints. The data for all the strains in Lot 1 (Group 1) is sufficient to describe the immunogenicity expected with the vaccine. The analytical plan was included in the protocol and agreement was reach with EMA and FDA.
| percentage of participants | Group 1 rLP2086 Lot 1 |
|---|---|
| PMB3175[A29]:Before Vaccination 1 (N= 269) | 17.5 (13.1 to 22.5) |
| PMB3175[A29]:1 Month after Vaccination 3 (N= 278) | 98.6 (96.4 to 99.6) |
| PMB3010[A06]:Before Vaccination 1 (N= 277) | 9.4 (6.2 to 13.5) |
| PMB3010[A06]:1 Month after Vaccination 3 (N= 280) | 95.7 (92.6 to 97.8) |
| PMB3040[A07]:Before Vaccination 1 (N= 269) | 43.1 (37.1 to 49.3) |
| PMB3040[A07]:1 Month after Vaccination 3 (N= 280) | 96.4 (93.5 to 98.3) |
| PMB824[A12]: Before Vaccination 1 (N= 280) | 3.9 (2.0 to 6.9) |
| PMB824[A12]:1 Month after Vaccination 3 (N= 277) | 75.1 (69.6 to 80.1) |
| PMB1672[A15]:Before Vaccination 1 (N= 270) | 20.7 (16.1 to 26.1) |
| PMB1672[A15]:1 Month after Vaccination 3 (N= 266) | 87.2 (82.6 to 91.0) |
| PMB1989[A19]:Before Vaccination 1 (N= 274) | 11.3 (7.8 to 15.7) |
| PMB1989[A19]:1 Month after Vaccination 3 (N= 275) | 92.7 (89.0 to 95.5) |
| PMB1256[B03]:Before Vaccination 1 (N= 280) | 4.3 (2.2 to 7.4) |
| PMB1256[B03]:1 Month after Vaccination 3 (N= 279) | 92.5 (88.7 to 95.3) |
| PMB866[B09]:Before Vaccination 1 (N= 277) | 15.2 (11.2 to 19.9) |
| PMB866[B09]:1 Month after Vaccination 3 (N= 276) | 86.2 (81.6 to 90.1) |
| PMB431[B15]:Before Vaccination 1 (N= 275) | 28.7 (23.5 to 34.5) |
| PMB431[B15]:1 Month after Vaccination 3 (N= 281) | 98.2 (95.9 to 99.4) |
| PMB648[B16]:Before Vaccination 1 (N= 276) | 7.6 (4.8 to 11.4) |
| PMB648[B16]:1 Month after Vaccination 3 (N= 278) | 81.7 (76.6 to 86.0) |
Groups 2 and 3 were included for the Lot consistency analysis for primary strains only (hSBA geometric mean titer). The immunogenicity of two MnB strains in lots 1, 2, 3 were required to test for lot consistency. These data are presented separately in the other endpoints. The data for all the strains in Lot 1 (Group 1) is sufficient to describe the immunogenicity expected with the vaccine. The analytical plan was included in the protocol and agreement was reach with EMA and FDA.
| percentage of participants | Group 1 rLP2086 Lot 1 |
|---|---|
| Before Vaccination 1: PMB3175[A29] 1:4 (N=269) | 19.0 (14.5 to 24.2) |
| 1 month after Vac 3: PMB3175[A29] 1:4 (N=278) | 98.6 (96.4 to 99.6) |
| Before Vaccination 1: PMB3175[A29] 1:8 (N=269) | 17.5 (13.1 to 22.5) |
| 1 month after Vac 3: PMB3175[A29] 1:8 (N=278) | 98.6 (96.4 to 99.6) |
| Before Vaccination 1: PMB3175[A29] 1:16 (N=269) | 16.7 (12.5 to 21.7) |
| 1 month after Vac 3: PMB3175[A29] 1:16 (N=278) | 98.6 (96.4 to 99.6) |
| Before Vaccination 1: PMB3175[A29] 1:32 (N=269) | 10.8 (7.3 to 15.1) |
| 1 month after Vac 3: PMB3175[A29] 1:32 (N=278) | 97.5 (94.9 to 99.0) |
| Before Vaccination 1: PMB3175[A29] 1:64 (N=269) | 4.8 (2.6 to 8.1) |
| 1 month after Vac 3: PMB3175[A29] 1:64 (N=278) | 86.0 (81.3 to 89.8) |
| Before Vaccination 1: PMB3175[A29] 1:128 (N=269) | 1.1 (0.2 to 3.2) |
| 1 month after Vac 3: PMB3175[A29] 1:128 (N=278) | 52.2 (46.1 to 58.2) |
| Before Vaccination 1: PMB3010[A06] 1:4 (N=277) | 9.7 (6.5 to 13.9) |
| 1 month after Vac 3: PMB3010[A06] 1:4 (N=280) | 96.1 (93.1 to 98.0) |
| Before Vaccination 1: PMB3010[A06] 1:8 (N=277) | 9.7 (6.5 to 13.9) |
| 1 month after Vac 3: PMB3010[A06] 1:8 (N=280) | 96.1 (93.1 to 98.0) |
| Before Vaccination 1: PMB3010[A06] 1:16 (N=277) | 9.4 (6.2 to 13.5) |
| 1 month after Vac 3: PMB3010[A06] 1:16 (N=280) | 95.7 (92.6 to 97.8) |
| Before Vaccination 1: PMB3010[A06] 1:32 (N=277) | 6.1 (3.6 to 9.6) |
| 1 month after Vac 3: PMB3010 [A06] 1:32 (N=280) | 93.6 (90.0 to 96.1) |
| Before Vaccination 1: PMB3010[A06] 1:64 (N=277) | 2.9 (1.3 to 5.6) |
| 1 month after Vac 3: PMB3010[A06] 1:64 (N=280) | 78.2 (72.9 to 82.9) |
| Before Vaccination 1: PMB3010[A06] 1:128 (N=277) | 1.4 (0.4 to 3.7) |
| 1 month after Vac 3: PMB3010[A06] 1:128 (N=280) | 44.3 (38.4 to 50.3) |
| Before Vaccination 1: PMB3040[A07] 1:4 (N=269) | 43.1 (37.1 to 49.3) |
| 1 month after Vac 3: PMB3040[A07] 1:4 (N=280) | 96.4 (93.5 to 98.3) |
| Before Vaccination 1: PMB3040[A07] 1:8 (N=269) | 43.1 (37.1 to 49.3) |
| 1 month after Vac 3: PMB3040[A07] 1:8 (N=280) | 96.4 (93.5 to 98.3) |
| Before Vaccination 1: PMB3040[A07] 1:16 (N=269) | 42.8 (36.8 to 48.9) |
| 1 month after Vac 3: PMB3040[A07] 1:16 (N=280) | 96.4 (93.5 to 98.3) |
| Before Vaccination 1: PMB3040[A07] 1:32 (N=269) | 37.2 (31.4 to 43.3) |
| 1 month after Vac 3: PMB3040[A07] 1:32 (N=280) | 93.6 (90.0 to 96.1) |
| Before Vaccination 1: PMB3040[A07] 1:64 (N=269) | 21.6 (16.8 to 27.0) |
| 1 month after Vac 3: PMB3040[A07] 1:64 (N=280) | 78.2 (72.9 to 82.9) |
| Before Vaccination 1: PMB3040[A07] 1:128 (N=269) | 5.6 (3.2 to 9.0) |
| 1 month after Vac 3: PMB3040[A07] 1:128 (N=280) | 30.4 (25.0 to 36.1) |
| Before Vaccination 1: PMB824[A12] 1:4 (N=280) | 5.4 (3.0 to 8.7) |
| 1 month after Vac 3: PMB824[A12] 1:4 (N=277) | 77.6 (72.2 to 82.4) |
| Before Vaccination 1: PMB824[A12] 1:8 (N=280) | 4.6 (2.5 to 7.8) |
| 1 month after Vac 3: PMB824[A12] 1:8 (N=277) | 77.3 (71.9 to 82.1) |
| Before Vaccination 1: PMB824[A12] 1:16 (N=280) | 3.9 (2.0 to 6.9) |
| 1 month after Vac 3: PMB824[A12] 1:16 (N=277) | 75.1 (69.6 to 80.1) |
| Before Vaccination 1: PMB824[A12] 1:32 (N=280) | 2.5 (1.0 to 5.1) |
| 1 month after Vac 3: PMB824[A12] 1:32 (N=277) | 51.3 (45.2 to 57.3) |
| Before Vaccination 1: PMB824[A12] 1:64 (N=280) | 0.0 (0.0 to 1.3) |
| 1 month after Vac 3: PMB824[A12] 1:64 (N=277) | 19.5 (15.0 to 24.7) |
| Before Vaccination 1: PMB824[A12] 1:128 (N=280) | 0.0 (0.0 to 1.3) |
| 1 month after Vac 3: PMB824[A12] 1:128 (N=277) | 1.8 (0.6 to 4.2) |
| Before Vaccination 1: PMB1672[A15] 1:4 (N=270) | 22.6 (17.7 to 28.1) |
| 1 month after Vac 3: PMB1672[A15] 1:4 (N=266) | 87.2 (82.6 to 91.0) |
| Before Vaccination 1: PMB1672[A15] 1:8 (N=270) | 20.7 (16.1 to 26.1) |
| 1 month after Vac 3: PMB1672[A15] 1:8 (N=266) | 87.2 (82.6 to 91.0) |
| Before Vaccination 1: PMB1672[A15] 1:16 (N=270) | 17.0 (12.8 to 22.1) |
| 1 month after Vac 3: PMB1672[A15] 1:16 (N=266) | 85.0 (80.1 to 89.0) |
| Before Vaccination 1: PMB1672[A15] 1:32 (N=270) | 13.3 (9.5 to 18.0) |
| 1 month after Vac 3: PMB1672[A15] 1:32 (N=266) | 71.4 (65.6 to 76.8) |
| Before Vaccination 1: PMB1672[A15] 1:64 (N=270) | 3.7 (1.8 to 6.7) |
| 1 month after Vac 3: PMB1672[A15] 1:64 (N=266) | 40.2 (34.3 to 46.4) |
| Before Vaccination 1: PMB1672[A15] 1:128 (N=270) | 0.4 (0.0 to 2.0) |
| 1 month after Vac 3: PMB1672[A15] 1:128 (N=266) | 10.5 (7.1 to 14.9) |
| Before Vaccination 1: PMB1989[A19] 1:4 (N=274) | 20.8 (16.2 to 26.1) |
| 1 month after Vac 3: PMB1989[A19] 1:4 (N=275) | 93.8 (90.3 to 96.4) |
| Before Vaccination 1: PMB1989[A19] 1:8 (N=274) | 18.6 (14.2 to 23.7) |
| 1 month after Vac 3: PMB1989[A19] 1:8 (N=275) | 93.8 (90.3 to 96.4) |
| Before Vaccination 1: PMB1989[A19] 1:16 (N=274) | 11.3 (7.8 to 15.7) |
| 1 month after Vac 3: PMB1989[A19] 1:16 (N=275) | 92.7 (89.0 to 95.5) |
| Before Vaccination 1: PMB1989[A19] 1:32 (N=274) | 5.8 (3.4 to 9.3) |
| 1 month after Vac 3: PMB1989[A19] 1:32 (N=275) | 85.5 (80.7 to 89.4) |
| Before Vaccination 1: PMB1989[A19] 1:64 (N=274) | 1.8 (0.6 to 4.2) |
| 1 month after Vac 3: PMB1989[A19] 1:64 (N=275) | 60.0 (53.9 to 65.8) |
| Before Vaccination 1: PMB1989[A19] 1:128 (N=274) | 0.4 (0.0 to 2.0) |
| 1 month after Vac 3: PMB1989[A19] 1:128 (N=275) | 33.1 (27.6 to 39.0) |
| Before Vaccination 1: PMB1256[B03] 1:4 (N=280) | 5.0 (2.8 to 8.2) |
| 1 month after Vac 3: PMB1256[B03] 1:4 (N=279) | 92.5 (88.7 to 95.3) |
| Before Vaccination 1: PMB1256[B03] 1:8 (N=280) | 4.3 (2.2 to 7.4) |
| 1 month after Vac 3: PMB1256[B03] 1:8 (N=279) | 92.5 (88.7 to 95.3) |
| Before Vaccination 1: PMB1256[B03] 1:16 (N=280) | 4.3 (2.2 to 7.4) |
| 1 month after Vac 3: PMB1256[B03] 1:16 (N=279) | 92.1 (88.3 to 95.0) |
| Before Vaccination 1: PMB1256[B03] 1:32 (N=280) | 3.9 (2.0 to 6.9) |
| 1 month after Vac 3: PMB1256[B03] 1:32 (N=279) | 81.4 (76.3 to 85.8) |
| Before Vaccination 1: PMB1256[B03] 1:64 (N=280) | 2.9 (1.2 to 5.6) |
| 1 month after Vac 3: PMB1256[B03] 1:64 (N=279) | 60.6 (54.6 to 66.3) |
| Before Vaccination 1: PMB1256[B03] 1:128 (N=280) | 0.4 (0.0 to 2.0) |
| 1 month after Vac 3: PMB1256[B03] 1:128 (N=279) | 29.4 (24.1 to 35.1) |
| Before Vaccination 1: PMB866[B09] 1:4 (N=277) | 15.5 (11.5 to 20.3) |
| 1 month after Vac 3: PMB866[B09] 1:4 (N=276) | 86.6 (82.0 to 90.4) |
| Before Vaccination 1: PMB866[B09] 1:8 (N=277) | 15.2 (11.2 to 19.9) |
| 1 month after Vac 3: PMB866[B09] 1:8 (N=276) | 86.2 (81.6 to 90.1) |
| Before Vaccination 1: PMB866[B09] 1:16 (N=277) | 13.7 (9.9 to 18.3) |
| 1 month after Vac 3: PMB866[B09] 1:16 (N=276) | 83.7 (78.8 to 87.9) |
| Before Vaccination 1: PMB866[B09] 1:32 (N=277) | 8.7 (5.6 to 12.6) |
| 1 month after Vac 3: PMB866[B09] 1:32 (N=276) | 54.0 (47.9 to 60.0) |
| Before Vaccination 1: PMB866[B09] 1:64 (N=277) | 0.4 (0.0 to 2.0) |
| 1 month after Vac 3: PMB866[B09] 1:64 (N=276) | 21.4 (16.7 to 26.7) |
| Before Vaccination 1: PMB866[B09] 1:128 (N=277) | 0.0 (0.0 to 1.3) |
| 1 month after Vac 3: PMB866[B09] 1:128 (N=276) | 4.3 (2.3 to 7.5) |
| Before Vaccination 1: PMB431[B15] 1:4 (N=275) | 30.5 (25.2 to 36.4) |
| 1 month after Vac 3: PMB431[B15] 1:4 (N=281) | 98.2 (95.9 to 99.4) |
| Before Vaccination 1: PMB431[B15] 1:8 (N=275) | 28.7 (23.5 to 34.5) |
| 1 month after Vac 3: PMB431[B15] 1:8 (N=281) | 98.2 (95.9 to 99.4) |
| Before Vaccination 1: PMB431[B15] 1:16 (N=275) | 27.6 (22.4 to 33.3) |
| 1 month after Vac 3: PMB431[B15] 1:16 (N=281) | 97.5 (94.9 to 99.0) |
| Before Vaccination 1: PMB431[B15] 1:32 (N=275) | 21.8 (17.1 to 27.2) |
| 1 month after Vac 3: PMB431[B15] 1:32 (N=281) | 85.1 (80.3 to 89.0) |
| Before Vaccination 1: PMB431[B15] 1:64 (N=275) | 8.4 (5.4 to 12.3) |
| 1 month after Vac 3: PMB431[B15] 1:64 (N=281) | 56.2 (50.2 to 62.1) |
| Before Vaccination 1: PMB431[B15] 1:128 (N=275) | 0.4 (0.0 to 2.0) |
| 1 month after Vac 3: PMB431[B15] 1:128 (N=281) | 19.2 (14.8 to 24.3) |
| Before Vaccination 1: PMB648[B16] 1:4 (N=276) | 8.7 (5.7 to 12.7) |
| 1 month after Vac 3: PMB648[B16] 1:4 (N=278) | 82.7 (77.8 to 87.0) |
| Before Vaccination 1: PMB648[B16] 1:8 (N=276) | 7.6 (4.8 to 11.4) |
| 1 month after Vac 3: PMB648[B16] 1:8 (N=278) | 81.7 (76.6 to 86.0) |
| Before Vaccination 1: PMB648[B16] 1:16 (N=276) | 7.6 (4.8 to 11.4) |
| 1 month after Vac 3: PMB648[B16] 1:16 (N=278) | 79.9 (74.7 to 84.4) |
| Before Vaccination 1: PMB648[B16] 1:32 (N=276) | 6.2 (3.6 to 9.7) |
| 1 month after Vac 3: PMB648[B16] 1:32 (N=278) | 54.0 (47.9 to 59.9) |
| Before Vaccination 1: PMB648[B16] 1:64 (N=276) | 1.8 (0.6 to 4.2) |
| 1 month after Vac 3: PMB648[B16] 1:64 (N=278) | 24.1 (19.2 to 29.6) |
| Before Vaccination 1: PMB648[B16] 1:128 (N=276) | 0.4 (0.0 to 2.0) |
| 1 month after Vac 3: PMB648[B16] 1:128 (N=278) | 5.8 (3.3 to 9.2) |
Groups 2 and 3 were included for the Lot consistency analysis for primary strains only (hSBA geometric mean titer). The immunogenicity of two MnB strains in lots 1, 2, 3 were required to test for lot consistency. These data are presented separately in the other endpoints. The data for all the strains in Lot 1 (Group 1) is sufficient to describe the immunogenicity expected with the vaccine. The analytical plan was included in the protocol and agreement was reach with EMA and FDA.
| titer | Group 1 rLP2086 Lot 1 |
|---|---|
| PMB3175[A29]:Before Vaccination 1 (N= 269) | 5.7 (5.16 to 6.28) |
| PMB3175[A29]:1 Month after Vaccination 3 (N= 278) | 93.5 (84.79 to 103.09) |
| PMB3010[A06]:Before Vaccination 1 (N= 277) | 9.3 (8.68 to 9.91) |
| PMB3010[A06]:1 Month after Vaccination 3 (N= 280) | 78.6 (70.94 to 87.08) |
| PMB3040[A07]:Before Vaccination 1 (N= 269) | 11.4 (9.75 to 13.23) |
| PMB3040[A07]:1 Month after Vaccination 3 (N= 280) | 63.5 (57.93 to 69.66) |
| PMB824[A12]: Before Vaccination 1 (N= 280) | 8.4 (8.14 to 8.59) |
| PMB824[A12]:1 Month after Vaccination 3 (N= 277) | 22.3 (20.37 to 24.45) |
| PMB1672[A15]:Before Vaccination 1 (N= 270) | 5.9 (5.32 to 6.46) |
| PMB1672[A15]:1 Month after Vaccination 3 (N= 266) | 31.0 (27.43 to 35.07) |
| PMB1989[A19]:Before Vaccination 1 (N= 274) | 9.1 (8.70 to 9.62) |
| PMB1989[A19]:1 Month after Vaccination 3 (N= 275) | 57.6 (51.30 to 64.60) |
| PMB1256[B03]:Before Vaccination 1 (N= 280) | 4.5 (4.19 to 4.75) |
| PMB1256[B03]:1 Month after Vaccination 3 (N= 279) | 51.7 (45.36 to 58.89) |
| PMB866[B09]:Before Vaccination 1 (N= 277) | 5.2 (4.82 to 5.62) |
| PMB866[B09]:1 Month after Vaccination 3 (N= 276) | 22.9 (20.48 to 25.63) |
| PMB431[B15]:Before Vaccination 1 (N= 275) | 7.3 (6.49 to 8.23) |
| PMB431[B15]:1 Month after Vaccination 3 (N= 281) | 47.7 (43.66 to 52.16) |
| PMB648[B16]:Before Vaccination 1 (N= 276) | 4.7 (4.39 to 5.05) |
| PMB648[B16]:1 Month after Vaccination 3 (N= 278) | 22.1 (19.60 to 24.98) |
Groups 2 and 3 were included for the Lot consistency analysis for primary strains only (hSBA geometric mean titer). The immunogenicity of two MnB strains in lots 1, 2 ,3 were required to test for lot consistency. These data are presented separately in the other endpoints. The data for all the strains in Lot 1 (Group 1) is sufficient to describe the immunogenicity expected with the vaccine. The analytical plan was included in the protocol and agreement was reach with EMA and FDA.
| percentage of participants | Group 1 rLP2086 Lot 1 |
|---|---|
| Before First Vaccination (N= 1088) | 1.1 (0.6 to 1.9) |
| 1 Month after Vaccination 2 (N= 1122) | 54.1 (51.1 to 57.0) |
Groups 2 and 3 were included for the Lot consistency analysis for primary strains only (hSBA geometric mean titer). The immunogenicity of two MnB strains in lots 1, 2, 3 were required to test for lot consistency. These data are presented separately in the other endpoints. The data for all the strains in Lot 1 (Group 1) is sufficient to describe the immunogenicity expected with the vaccine. The analytical plan was included in the protocol and agreement was reach with EMA and FDA.
| percentage of participants | Group 1 rLP2086 Lot 1 |
|---|---|
| PMB80[A22] (N=1223) | 73.8 (71.2 to 76.2) |
| PMB2001[A56] (N=1122) | 84.8 (82.5 to 86.8) |
| PMB2948[B24] (N=1201) | 56.2 (53.3 to 59.0) |
| PMB2707[B44] (N=1197) | 55.9 (53.0 to 58.7) |
| percentage of participants | Group 2 rLP2086 Lot 2 | Group 3 rLP2086 Lot 3 |
|---|---|---|
| PMB80[A22]:1Month after Vaccination 2 (N=493, 473) | 71.2 (67.0 to 75.2) | 74.6 (70.5 to 78.5) |
| PMB80[A22]:1Month after Vaccination 3 (N=501, 478) | 83.8 (80.3 to 86.9) | 86.0 (82.5 to 89.0) |
| PMB2948[B24]:1Month after Vaccination 2(N=490,463) | 56.7 (52.2 to 61.2) | 56.8 (52.2 to 61.4) |
| PMB2948[B24]:1Month after Vaccination 3(N=507,472) | 76.5 (72.6 to 80.2) | 78.4 (74.4 to 82.0) |
| titer | Group 1 rLP2086 Lot 1 | Group 2 rLP2086 Lot 2 | Group 3 rLP2086 Lot 3 |
|---|---|---|---|
| PMB80[A22]: Before Vac 1 (N=1238, 502, 479) | 12.6 (12.08 to 13.14) | 12.9 (12.06 to 13.79) | 12.2 (11.43 to 13.04) |
| PMB80[A22]: 1 Month after Vac 2 (N=1263, 510, 487) | 50.4 (47.76 to 53.09) | 47.7 (43.82 to 51.97) | 49.6 (45.58 to 53.99) |
| PMB2001[A56]: Before Vac 1 (N=1135, 0, 0) | 8.4 (7.80 to 9.05) | NA (NA to NA) | NA (NA to NA) |
| PMB2001[A56]: 1 Month after Vac 2 (N=1222, 0, 0) | 131.2 (124.03 to 138.70) | NA (NA to NA) | NA (NA to NA) |
| PMB2948[B24]: Before Vac 1 (N=1264, 510, 486) | 4.5 (4.37 to 4.60) | 4.6 (4.43 to 4.85) | 4.6 (4.43 to 4.88) |
| PMB2948[B24]: 1 Month after Vac 2 (N=1216,499,470) | 14.3 (13.45 to 15.31) | 14.5 (13.23 to 15.98) | 15.2 (13.75 to 16.85) |
| PMB2707[B44]: Before Vac 1 (N=1230, 0, 0) | 4.3 (4.17 to 4.34) | NA (NA to NA) | NA (NA to NA) |
| PMB2707[B44]: 1 Month after Vac 2 (N=1204, 0, 0) | 17.1 (15.80 to 18.60) | NA (NA to NA) | NA (NA to NA) |
| percentage of participants | Group 1 rLP2086 Lot 1 | Group 2 rLP2086 Lot 2 | Group 3 rLP2086 Lot 3 |
|---|---|---|---|
| Before Vac 1: PMB80[A22] 1:16(N=1238, 502, 479) | 33.2 (30.6 to 35.9) | 34.9 (30.7 to 39.2) | 31.7 (27.6 to 36.1) |
| 1 month afterVac2:PMB80[A22]1:16(N=1263,510,487) | 94.3 (92.9 to 95.5) | 92.7 (90.1 to 94.8) | 94.7 (92.3 to 96.5) |
| 1 month after Vac3:PMB80[A22]1:16(N=1266, 518,492) | 97.8 (96.8 to 98.5) | 97.3 (95.5 to 98.5) | 98.2 (96.6 to 99.2) |
| Before Vac 1: PMB2001[A56] 1:8(N=1135, 0, 0) | 27.5 (24.9 to 30.2) | NA (NA to NA) | NA (NA to NA) |
| 1 month after Vac2:PMB2001[A56]1:8(N=1222, 0, 0) | 99.1 (98.4 to 99.5) | NA (NA to NA) | NA (NA to NA) |
| 1 month after Vac3:PMB2001[A56]1:8(N=1229, 0, 0) | 99.5 (98.9 to 99.8) | NA (NA to NA) | NA (NA to NA) |
| Before Vac 1: PMB2948[B24]1:8(N=1264, 510, 486) | 6.4 (5.1 to 7.9) | 8.6 (6.3 to 11.4) | 8.4 (6.1 to 11.3) |
| 1 monthafterVac2:PMB2948[B24]1:8(N=1216,499,470) | 66.4 (63.6 to 69.0) | 70.1 (65.9 to 74.1) | 70.2 (65.9 to 74.3) |
| 1 monthafterVac3:PMB2948[B24]1:8(N=1250,516,479) | 87.1 (85.1 to 88.9) | 87.6 (84.4 to 90.3) | 90.0 (86.9 to 92.5) |
| Before Vac 1: PMB2707[B44] 1:8(N=1230, 0, 0) | 3.6 (2.6 to 4.8) | NA (NA to NA) | NA (NA to NA) |
| 1 month after Vac2:PMB2707[B44]1:8(N=1204, 0, 0) | 64.0 (61.3 to 66.8) | NA (NA to NA) | NA (NA to NA) |
| 1 month after Vac3:PMB2707[B44]1:8(N=1210, 0, 0) | 89.3 (87.4 to 90.9) | NA (NA to NA) | NA (NA to NA) |
Results for PMB80\[A22\] 1:16, PMB2001\[A56\] 1:8, PMB2948\[B24\] 1:8 and PMB2707\[B44\] 1:8 are reported under secondary outcome measure 'Percentage of Participants With hSBA Titers \>=LLOQ for 4 Primary Test Strains Before First Vaccination, 1 Month After Second and Third Bivalent rLP2086 Vaccination.
| percentage of participants | Group 1 rLP2086 Lot 1 | Group 2 rLP2086 Lot 2 | Group 3 rLP2086 Lot 3 |
|---|---|---|---|
| Before Vac 1:PMB80[A22] 1:4(N=1238, 502, 479) | 36.2 (33.5 to 38.9) | 39.6 (35.3 to 44.1) | 36.7 (32.4 to 41.2) |
| 1 month after Vac2:PMB80[A22]1:4(N=1263, 510, 487) | 94.9 (93.6 to 96.1) | 93.7 (91.3 to 95.7) | 95.5 (93.2 to 97.1) |
| 1 month after Vac3:PMB80[A22]1:4(N=1266, 518, 492) | 97.9 (97.0 to 98.7) | 98.1 (96.5 to 99.1) | 98.4 (96.8 to 99.3) |
| Before Vac 1: PMB80[A22] 1:8(N=1238, 502, 479) | 34.8 (32.2 to 37.5) | 39.0 (34.8 to 43.5) | 34.7 (30.4 to 39.1) |
| 1 month after Vac2:PMB80[A22]1:8(N=1263, 510, 487) | 94.7 (93.3 to 95.9) | 93.5 (91.0 to 95.5) | 95.5 (93.2 to 97.1) |
| 1 month after Vac3:PMB80[A22]1:8(N=1266, 518, 492) | 97.9 (97.0 to 98.7) | 98.1 (96.5 to 99.1) | 98.4 (96.8 to 99.3) |
| Before Vac 1: PMB80[A22] 1:32(N=1238, 502, 479) | 20.9 (18.7 to 23.3) | 21.7 (18.2 to 25.6) | 19.8 (16.4 to 23.7) |
| 1 month after Vac2:PMB80[A22]1:32(N=1263, 510,487) | 81.9 (79.7 to 84.0) | 79.4 (75.6 to 82.8) | 80.7 (76.9 to 84.1) |
| 1 month after Vac3:PMB80[A22]1:32(N=1266,518,492) | 93.0 (91.4 to 94.3) | 92.1 (89.4 to 94.3) | 93.1 (90.5 to 95.2) |
| Before Vac 1: PMB80[A22] 1:64(N=1238, 502, 479) | 8.5 (7.0 to 10.2) | 9.6 (7.1 to 12.5) | 5.4 (3.6 to 7.9) |
| 1 month after Vac2:PMB80[A22]1:64(N=1263,510,487) | 51.8 (49.0 to 54.6) | 49.6 (45.2 to 54.0) | 51.5 (47.0 to 56.1) |
| 1 month after Vac3:PMB80[A22]1:64(N=1266,518,492) | 75.3 (72.8 to 77.6) | 75.5 (71.5 to 79.1) | 73.6 (69.4 to 77.4) |
| Before Vac 1: PMB80[A22] 1:128(N=1238, 502,479) | 2.0 (1.3 to 3.0) | 2.0 (1.0 to 3.6) | 2.5 (1.3 to 4.3) |
| 1 month after Vac2:PMB80[A22]1:128(N=1263,510,487) | 24.5 (22.1 to 26.9) | 23.5 (19.9 to 27.5) | 24.4 (20.7 to 28.5) |
| 1 month after Vac3:PMB80[A22]1:128(N=1266,518,492) | 48.3 (45.6 to 51.1) | 46.3 (42.0 to 50.7) | 49.2 (44.7 to 53.7) |
| Before Vac 1: PMB2001[A56] 1:4(N=1135, 0, 0) | 29.5 (26.9 to 32.3) | NA (NA to NA) | NA (NA to NA) |
| 1 month after Vac2:PMB2001[A56]1:4(N=1222, 0, 0) | 99.1 (98.4 to 99.5) | NA (NA to NA) | NA (NA to NA) |
| 1 month after Vac3:PMB2001[A56]1:4(N=1229, 0, 0) | 99.5 (98.9 to 99.8) | NA (NA to NA) | NA (NA to NA) |
| Before Vac 1: PMB2001[A56] 1:16(N=1135, 0, 0) | 27.4 (24.8 to 30.1) | NA (NA to NA) | NA (NA to NA) |
| 1 month after Vac2:PMB2001[A56]1:16(N=1222,0,0) | 99.1 (98.4 to 99.5) | NA (NA to NA) | NA (NA to NA) |
| 1 month after Vac3:PMB2001[A56]1:16(N=1229,0,0) | 99.4 (98.8 to 99.8) | NA (NA to NA) | NA (NA to NA) |
| Before Vac 1: PMB2001[A56] ] 1:32(N=1135, 0, 0) | 25.6 (23.0 to 28.2) | NA (NA to NA) | NA (NA to NA) |
| 1 month after Vac2:PMB2001[A56] 1:32(N=1222,0,0) | 97.2 (96.1 to 98.1) | NA (NA to NA) | NA (NA to NA) |
| 1 month after Vac3:PMB2001[A56]1:32(N=1229,0,0) | 98.6 (97.8 to 99.2) | NA (NA to NA) | NA (NA to NA) |
| Before Vac 1: PMB2001[A56] 1:64(N=1135, 0, 0) | 17.1 (14.9 to 19.4) | NA (NA to NA) | NA (NA to NA) |
| 1 month afterVac2:PMB2001[A56]1:64(N=1222,0,0) | 89.4 (87.6 to 91.1) | NA (NA to NA) | NA (NA to NA) |
| 1 month after Vac3:PMB2001[A56]1:64(N=1229,0,0) | 94.5 (93.0 to 95.7) | NA (NA to NA) | NA (NA to NA) |
| Before Vac 1: PMB2001[A56] 1:128(N=1135, 0, 0) | 6.4 (5.1 to 8.0) | NA (NA to NA) | NA (NA to NA) |
| 1 month after Vac2:PMB2001[A56]1:128(N=1222,0,0) | 63.4 (60.6 to 66.1) | NA (NA to NA) | NA (NA to NA) |
| 1 month afterVac3:PMB2001[A56]1:128(N=1229,0,0) | 82.9 (80.7 to 85.0) | NA (NA to NA) | NA (NA to NA) |
| Before Vac 1: PMB2948[B24] 1:4(N=1264, 510, 486) | 6.8 (5.5 to 8.3) | 10.2 (7.7 to 13.2) | 9.5 (7.0 to 12.4) |
| 1 month after Vac2:PMB2948[B24]1:4(N=1216,499,470) | 69.2 (66.6 to 71.8) | 72.9 (68.8 to 76.8) | 74.0 (69.8 to 78.0) |
| 1 month after Vac3:PMB2948[B24]1:4(N=1250,516,479) | 88.9 (87.0 to 90.6) | 89.9 (87.0 to 92.4) | 91.6 (88.8 to 94.0) |
| Before Vac 1: PMB2948[B24] 1:16(N=1264, 510, 486) | 5.4 (4.2 to 6.8) | 7.5 (5.3 to 10.1) | 7.0 (4.9 to 9.6) |
| 1 month afterVac2:PMB2948[B24]1:16(N=1216,499,470) | 60.0 (57.2 to 62.8) | 61.5 (57.1 to 65.8) | 62.1 (57.6 to 66.5) |
| 1 month afterVac3:PMB2948[B24]1:16(N=1250,516,479) | 82.6 (80.4 to 84.7) | 81.2 (77.6 to 84.5) | 83.1 (79.4 to 86.3) |
| Before Vac 1: PMB2948[B24] 1:32(N=1264, 510, 486) | 2.8 (2.0 to 3.9) | 3.9 (2.4 to 6.0) | 3.7 (2.2 to 5.8) |
| 1 month afterVac2:PMB2948[B24]1:32(N=1216,499,470) | 33.0 (30.3 to 35.7) | 34.5 (30.3 to 38.8) | 35.5 (31.2 to 40.0) |
| 1 month afterVac3:PMB2948[B24]1:32(N=1250,516,479) | 52.1 (49.3 to 54.9) | 54.8 (50.4 to 59.2) | 54.1 (49.5 to 58.6) |
| Before Vac 1:PMB2948[B24] 1:64(N=1264, 510, 486) | 1.3 (0.7 to 2.0) | 1.2 (0.4 to 2.5) | 1.9 (0.9 to 3.5) |
| 1 monthafterVac2:PMB2948[B24]1:64(N=1216,499,470) | 15.3 (13.3 to 17.4) | 13.0 (10.2 to 16.3) | 15.3 (12.2 to 18.9) |
| 1 month afterVac3:PMB2948[B24]1:64(N=1250,516,479) | 22.8 (20.5 to 25.2) | 27.5 (23.7 to 31.6) | 25.3 (21.4 to 29.4) |
| Before Vac 1:PMB2948[B24] 1:128(N=1264, 510,486) | 0.5 (0.2 to 1.0) | 0.2 (0.0 to 1.1) | 0.4 (0.0 to 1.5) |
| 1 monthafterVac2:PMB2948[B24]1:128(N=1216,499,470) | 6.2 (4.9 to 7.7) | 5.2 (3.4 to 7.5) | 7.0 (4.9 to 9.7) |
| 1 monthafterVac3:PMB2948[B24]1:128(N=1250,516,479) | 8.9 (7.4 to 10.6) | 11.2 (8.6 to 14.3) | 8.6 (6.2 to 11.4) |
| Before Vac 1: PMB2707[B44] 1:4(N=1230, 0, 0) | 4.6 (3.5 to 5.9) | NA (NA to NA) | NA (NA to NA) |
| 1 month after Vac2:PMB2707[B44]1:4(N=1204, 0,0) | 66.7 (64.0 to 69.4) | NA (NA to NA) | NA (NA to NA) |
| 1 month after Vac3:PMB2707[B44]1:4(N=1210, 0,0) | 90.4 (88.6 to 92.0) | NA (NA to NA) | NA (NA to NA) |
| Before Vac 1: PMB2707[B44] 1:16(N=1230, 0, 0) | 3.0 (2.1 to 4.1) | NA (NA to NA) | NA (NA to NA) |
| 1 month after Vac2:PMB2707[B44]1:16(N=1204,0,0) | 57.7 (54.9 to 60.5) | NA (NA to NA) | NA (NA to NA) |
| 1 month afterVac3:PMB2707[B44]1:16(N=1210,0, 0) | 86.8 (84.7 to 88.6) | NA (NA to NA) | NA (NA to NA) |
| Before Vac 1: PMB2707[B44] 1:32(N=1230, 0, 0) | 1.6 (1.0 to 2.5) | NA (NA to NA) | NA (NA to NA) |
| 1 month after Vac2:PMB2707[B44]1:32(N=1204,0,0) | 39.0 (36.3 to 41.9) | NA (NA to NA) | NA (NA to NA) |
| 1 month after Vac3:PMB2707[B44]1:32(N=1210,0,0) | 71.6 (68.9 to 74.1) | NA (NA to NA) | NA (NA to NA) |
| Before Vac 1:PMB2707[B44] 1:64(N=1230, 0, 0) | 0.7 (0.3 to 1.3) | NA (NA to NA) | NA (NA to NA) |
| 1 month after Vac2:PMB2707[B44]1:64(N=1204,0,0) | 23.3 (21.0 to 25.8) | NA (NA to NA) | NA (NA to NA) |
| 1 month after Vac3:PMB2707[B44]1:64(N=1210,0,0) | 54.5 (51.7 to 57.4) | NA (NA to NA) | NA (NA to NA) |
| Before Vac 1:PMB2707[B44] 1:128(N=1230, 0, 0) | 0.2 (0.0 to 0.6) | NA (NA to NA) | NA (NA to NA) |
| 1 month after Vac2:PMB2707[B44]1:128(N=1204,0,0) | 13.0 (11.2 to 15.1) | NA (NA to NA) | NA (NA to NA) |
| 1 month after Vac3:PMB2707[B44]1:128(N=1210,0,0) | 35.0 (32.4 to 37.8) | NA (NA to NA) | NA (NA to NA) |
No measurements were reported for this outcome.
| percentage of participants | Group 1 rLP2086 Lot 1 | Group 2 rLP2086 Lot 2 | Group 3 rLP2086 Lot 3 |
|---|---|---|---|
| PMB80[A22]: 1 Month after Vac 3(N=1225, 501, 478) | 91.43 (89.7 to 92.9) | 92.02 (89.3 to 94.2) | 93.51 (90.9 to 95.6) |
| PMB2001[A56]: 1 Month after Vac 3(N=1128, 0, 0) | 95.04 (93.6 to 96.2) | NA (NA to NA) | NA (NA to NA) |
| PMB2948[B24]: 1 Month after Vac 3(N=1235, 507,472) | 81.05 (78.8 to 83.2) | 79.09 (75.3 to 82.6) | 80.93 (77.1 to 84.4) |
| PMB2707[B44]: 1 Month after Vac 3(N=1203, 0, 0) | 86.62 (84.6 to 88.5) | NA (NA to NA) | NA (NA to NA) |
Collected over AEs/SAEs: recorded from first vaccination through 6 months after third vaccination. Participants recorded pre-specified reactogenicity events (local reactions, systemic events) in electronic diary within 7 days after first, second and third vaccination. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1 rLP2086 Lot 1 | — | 22/1,508 (1.5%) | 1,410/1,508 (93.5%) |
| Group 2 rLP2086 Lot 2 | — | 10/598 (1.7%) | 547/598 (91.5%) |
| Group 3 rLP2086 Lot 3 | — | 19/587 (3.2%) | 542/587 (92.3%) |
| Group 4 HAV/Saline | — | 22/897 (2.5%) | 655/897 (73%) |
| Event | Group 1 rLP2086 Lot 1 | Group 2 rLP2086 Lot 2 | Group 3 rLP2086 Lot 3 | Group 4 HAV/Saline |
|---|---|---|---|---|
| AppendicitisInfections and infestations | 0/1508 | 0/598 | 0/587 | 4/897 |
| CellulitisInfections and infestations | 0/1508 | 0/598 | 0/587 | 2/897 |
| Suicidal ideationPsychiatric disorders | 1/1508 | 0/598 | 1/587 | 2/897 |
| Abdominal painGastrointestinal disorders | 2/1508 | 0/598 | 1/587 | 0/897 |
| NauseaGastrointestinal disorders | 0/1508 | 0/598 | 1/587 | 0/897 |
| PancreatitisGastrointestinal disorders | 0/1508 | 0/598 | 1/587 | 0/897 |
| Appendicitis perforatedInfections and infestations | 1/1508 | 0/598 | 1/587 | 0/897 |
| AbscessInfections and infestations | 0/1508 | 0/598 | 1/587 | 0/897 |
| InfluenzaInfections and infestations | 0/1508 | 0/598 | 1/587 | 0/897 |
| Forearm fractureInjury, poisoning and procedural complications | 2/1508 | 0/598 | 1/587 | 0/897 |
| Event | Group 1 rLP2086 Lot 1 | Group 2 rLP2086 Lot 2 | Group 3 rLP2086 Lot 3 | Group 4 HAV/Saline |
|---|---|---|---|---|
| Pain at injection site -Any (reactogenicity event)Skin and subcutaneous tissue disorders | 1403/1504 | 544/597 | 541/585 | 525/897 |
| Headache -Any (reactogenicity event)General disorders | 1032/1504 | 379/597 | 392/585 | 477/893 |
| Fatigue -Any (reactogenicity event)General disorders | 1011/1504 | 380/597 | 369/585 | 454/893 |
| Muscle pain -Any (reactogenicity event)General disorders | 598/1504 | 205/597 | 210/585 | 254/893 |
| Chills-Any (reactogenicity event)General disorders | 566/1504 | 183/597 | 225/585 | 227/893 |
| Joint pain -Any (reactogenicity event)General disorders | 532/1504 | 170/597 | 191/585 | 209/893 |
| Swelling -Any (reactogenicity event)Skin and subcutaneous tissue disorders | 416/1504 | 161/597 | 158/585 | 26/893 |
| Redness -Any (reactogenicity event)Skin and subcutaneous tissue disorders | 365/1504 | 136/597 | 145/585 | 21/893 |
| Diarrhea-Any (reactogenicity event)General disorders | 294/1504 | 114/597 | 117/585 | 187/893 |
| Fever >=38.0 degrees C -Any (reactogenicity event)General disorders | 154/1504 | 52/597 | 57/585 | 46/892 |
Safety population included all the participants who received at least 1 dose of the investigational product (rLP2086 or HAV/saline) and had safety data available.
| Age, Continuous(Years) | Group 1 rLP2086 Lot 1 | Group 2 rLP2086 Lot 2 | Group 3 rLP2086 Lot 3 | Group 4 HAV/Saline | Total |
|---|---|---|---|---|---|
| Mean | 13.9 ± 2.6 | 14.0 ± 2.6 | 13.9 ± 2.6 | 13.9 ± 2.6 | 13.9 ± 2.6 |
| Sex: Female, Male(Participants) | Group 1 rLP2086 Lot 1 | Group 2 rLP2086 Lot 2 | Group 3 rLP2086 Lot 3 | Group 4 HAV/Saline | Total |
|---|---|---|---|---|---|
| Female | 737 | 286 | 274 | 443 | 1740 |
| Male | 771 | 312 | 313 | 454 | 1850 |
The record gives a start of Apr 2013, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2016, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: MenB-FHbp vaccine · 4CMenB vaccine